GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Shiller PE Ratio

Eledon Pharmaceuticals (FRA:2TK) Shiller PE Ratio : (As of Jun. 20, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Eledon Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Eledon Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals Shiller PE Ratio Chart

Eledon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eledon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eledon Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Eledon Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eledon Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's Shiller PE Ratio falls into.



Eledon Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Eledon Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Eledon Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.313/131.7762*131.7762
=-0.313

Current CPI (Mar. 2024) = 131.7762.

Eledon Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -604.822 100.560 -792.577
201409 -37.849 100.428 -49.664
201412 -36.787 99.070 -48.932
201503 -88.315 99.621 -116.821
201506 -57.736 100.684 -75.566
201509 -76.501 100.392 -100.417
201512 -72.870 99.792 -96.225
201603 -74.192 100.470 -97.310
201606 -1.201 101.688 -1.556
201609 -2.325 101.861 -3.008
201612 -1.513 101.863 -1.957
201703 -1.103 102.862 -1.413
201706 -380.629 103.349 -485.324
201709 -116.888 104.136 -147.913
201712 -9.515 104.011 -12.055
201803 -94.593 105.290 -118.389
201806 -94.295 106.317 -116.876
201809 -102.735 106.507 -127.110
201812 -139.547 105.998 -173.484
201903 -149.102 107.251 -183.198
201906 -100.357 108.070 -122.372
201909 -3.641 108.329 -4.429
201912 -5.112 108.420 -6.213
202003 -7.711 108.902 -9.331
202006 -2.433 108.767 -2.948
202009 -4.678 109.815 -5.614
202012 -0.320 109.897 -0.384
202103 -0.479 111.754 -0.565
202106 -0.415 114.631 -0.477
202109 -0.561 115.734 -0.639
202112 -0.531 117.630 -0.595
202203 -0.627 121.301 -0.681
202206 -0.615 125.017 -0.648
202209 -0.737 125.227 -0.776
202212 -3.861 125.222 -4.063
202303 -0.700 127.348 -0.724
202306 -0.369 128.729 -0.378
202309 -0.328 129.860 -0.333
202312 -0.266 129.419 -0.271
202403 -0.313 131.776 -0.313

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eledon Pharmaceuticals  (FRA:2TK) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Eledon Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eledon Pharmaceuticals (FRA:2TK) Business Description

Traded in Other Exchanges
Address
19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Eledon Pharmaceuticals (FRA:2TK) Headlines

No Headlines